Closing Soon
Devices, Drugs and Prevention as prevention of Cardiovascular outcomes in dialysis patients, sponsored by The Centre for Clinical Research and effective practice (CCRep), registered with the New Zealand Charities Commission (ref# CC21537)
Get in touch This trial recruits from February 2012 for 130 weeks
Mrs Brenda Luey
Phone: +64 (21) 824982
Fax: +64 (9) 2503878
Email: Jenny.Han@ccrep.org.nz
Address:
Centre for Clinical Research and effective practice
Middlemore Hospital
Private Bag 93311, Auckland 1640
Inclusion Criteria
Age: From 18 years
Gender: Both males and females
- Incident or prevalent patients treated with maintenance home haemodialysis or self care facility haemodialysis for end-stage kidney failure 2. Aged 18 years or older 3. Suitable for both low and standard dialysate [Na+] in the view of the treating physician 4. The person is willing to participate and has signed the Participant Information and Consent Form 5. Pre-dialysis plasma [Na+] > or = 135mM 6. The treating nephrologist agrees to the persons participation in the SOLID trial
Exclusion Criteria
- Haemodialysis treatments at a frequency of greater than 3.5 times per week
- Treatment with maintenance haemodiafiltration
- Life expectancy of less than 12 months
- Scheduled for live donor kidney transplantation within 12 months of entry to the study
- Considered by the treating nephrologist to have concomitant illnesses or conditions that limit or contraindicate study procedures and followup (e.g. frequent intra-dialytic hypotension requiring fluid resuscitation)
- Considered by the treating nephrologist to have a high chance of non-adherence to study treatments and non-attendance for procedures and follow-up
- Current enrolment in clinical studies involving antihypertensive medications, changes in HD operating parameters, or any other intervention that is likely to confound the outcome of this trial
- Documented obvious infiltrative cardiomyopathies (amyloid, glycogen storage disease), hereditary cardiomyopathies (hypertrophic cardiomyopathy), or moderate to severe aortic valve disease (aortic stenosis, regurgitation)
ACTRNACTRN12611000975998
A randomised, controlled trial of low sodium dialysate versus conventional sodium dialysate to reduce left ventricular mass index in patients receiving home haemodialysis
The effect of lower salt exposure on the cardiac structure and function of patients on home haemodialysis